

PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Ipsen Limited	08/08/2007
RECEIVING PARTY DATA	
Name:	Syntaxin Limited
Street Address:	Porton Down
City:	Salisbury, Wiltshire SP30JD, England
State/Country:	UNITED KINGDOM
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6461617
CORRESPONDENCE DATA	
Fax Number:	(202)408-5146
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	2022164816
Email:	craimund@mmmlaw.com
Correspondent Name:	Christopher W. Raimund
Address Line 1:	1401 H Street, NW
Address Line 2:	Suite 760
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20005
ATTORNEY DOCKET NUMBER:	21027
NAME OF SUBMITTER:	Christopher W. Raimund
Total Attachments: 34 source=HPA-Ipsen_to_Syntaxin_08-08-07#page1.tif source=HPA-Ipsen_to_Syntaxin_08-08-07#page2.tif source=HPA-Ipsen_to_Syntaxin_08-08-07#page3.tif source=HPA-Ipsen_to_Syntaxin_08-08-07#page4.tif source=HPA-Ipsen_to_Syntaxin_08-08-07#page5.tif	

OP \$40.00 6461617

500563887

PATENT
REEL: 021076 FRAME: 0562

source=HPA-lpsen_to_Syntaxin_08-08-07#page6.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page7.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page8.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page9.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page10.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page11.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page12.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page13.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page14.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page15.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page16.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page17.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page18.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page19.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page20.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page21.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page22.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page23.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page24.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page25.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page26.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page27.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page28.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page29.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page30.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page31.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page32.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page33.tif
source=HPA-lpsen_to_Syntaxin_08-08-07#page34.tif



SAVILLE & CO

NOTARIES


One Carey Lane
London EC2V 8AE
Telephone: +44 (0)20 7920 0000
Facsimile: +44 (0)20 7920 0088
www.savillenotaries.com
mail@savillenotaries.com

Richard Saville
Ian Campbell
Sophie Jenkins
Nicholas Thompson



TO ALL TO WHOM THESE PRESENTS SHALL COME, I
IAN RODERICK CAMPBELL of the City of London
NOTARY PUBLIC by royal authority duly admitted and sworn
DO HEREBY CERTIFY that the photographic copy hereunto
annexed is a true copy of the original **intellectual property
assignment** and of the notarial certificate of RICHARD JOHN
SAVILLE, Notary Public practising at London, England,
attached thereto of which it purports to be a copy, I having
carefully collated and compared the said copy with the said
original and found the same to agree therewith.

IN FAITH AND TESTIMONY WHEREOF I the said notary
have subscribed my name and set and affixed my seal of office
at London aforesaid this fourteenth day of September two
thousand and seven.



PATENT

REEL: 021076 FRAME: 0564

SAVILLE & CO

NOTARIES

One Carey Lane
London EC2V 8AE
Telephone: +44 (0)20 7920 0000
Facsimile: +44 (0)20 7920 0088
www.savillenotaries.com
mail@savillenotaries.com

Richard Saville
Ian Campbell
Sophie Jenkins
Nicholas Thompson



TO ALL TO WHOM THESE PRESENTS SHALL COME, I RICHARD JOHN SAVILLE of the City of London NOTARY PUBLIC by royal authority duly admitted and sworn DO HEREBY CERTIFY the genuineness of the signatures of ALISTAIR MICHAEL STOKES and JOHN CHARLES DAVIS subscribed to the **intellectual property assignment** hereunto annexed, such signatures being in the own, true, proper and respective handwriting of the said Alistair Michael Stokes and John Charles Davis whose personal identity I attest, both directors of **IPSEN LIMITED**, a company duly organised and existing in accordance with the laws of England and Wales under company registration number 03200696 and having its registered office at 190 Bath Road, Slough, Berkshire SL1 3XE, England and whose authority to execute the said intellectual property assignment, I the notary do also certify;


AND I DO FURTHER CERTIFY the genuineness of the signatures of Professor PATRICIA ANN TROOP and JOHN MICHAEL HARKER subscribed to the said annexed intellectual property assignment, such signatures being in the own, true, proper and respective handwriting of the said Professor Patricia Ann Troop and John Michael Harker, whose personal identity I attest, chief executive officer and secretary respectively of the **HEALTH PROTECTION AGENCY**, an independent agency established under the Health Protection Agency Act 2004, having its principal place of business at Porton Down, Salisbury, Wiltshire SP4 0JG, England and whose authority to execute the said intellectual property assignment, I the notary do also certify;

AND I DO FURTHER CERTIFY the genuineness of the signatures of CHARLES RICHARD PENN and PHILIP JAMES BOYD subscribed to the said annexed intellectual property assignment, such signatures being in the own, true, proper and respective handwriting of the said Charles Richard Penn and Philip James Boyd whose personal identity I attest, director and secretary respectively of **SYNTAXIN LIMITED**, a company duly organised and existing in accordance with the laws of England and Wales under company registration number 05480340 and having its registered office at Porton Down, Salisbury, Wiltshire SP30JD, England and whose authority to execute the said intellectual property assignment, I the notary do also certify;

AND I DO LASTLY CERTIFY that the said intellectual property assignment being so signed and delivered is duly executed as a deed in accordance with the provisions of English law.

IN FAITH AND TESTIMONY whereof I the said notary have subscribed my name and set and affixed my seal of office at London aforesaid this thirteenth day of September two thousand and seven.

W. Smith.



INTELLECTUAL PROPERTY ASSIGNMENT

THIS ASSIGNMENT is made the 8th day of August 2007

B E T W E E N:

- (1) **IPSEN LIMITED** whose principal place of business is at 190 Bath Road, Slough, Berkshire SL1 3XE ("**Ipsen**");
- (2) **HEALTH PROTECTION AGENCY** whose principal place of business is at Porton Down, Salisbury, Wiltshire SP4 0JG ("**HPA**"); and
- (3) **SYNTAXIN LIMITED** a company registered in England with company number 0580340 and having its registered office at Porton Down, Salisbury, Wiltshire SP4 0JD ("**Syntaxin**").

WHEREAS:

- (A) HPA and Ipsen (together "Assignors") are the joint proprietors of the patents and patent applications set out in Schedule 1 hereto ("Patents") and Schedule 2 hereto ("Ipsen Assigned Patents").
- (B) Ipsen is the sole proprietor of the Licensed Intellectual Property (as defined below).
- (C) The parties entered into a variation agreement dated 10 November 2005 (the "Variation Agreement") pursuant to which Ipsen granted authority to the HPA to sub-licence to Syntaxin the Licensed Intellectual Property and Ipsen's rights in the Patents and Ipsen Assigned Patents on a royalty free basis.
- (D) Under the terms of the Variation Agreement, and a licence agreement entered into between the parties dated 10 November 2005 ("Syntaxin Licence Agreement") it was agreed that if Syntaxin issued shares on the Second Subscription (as defined in the Subscription Agreement referred to below), the Assignors would assign to Syntaxin the Patents, and Ipsen would assign to Syntaxin the Licensed Intellectual Property and its right, title and interest in the Ipsen Assigned Patents.
- (E) As it has now been agreed that such shares will be issued by Syntaxin, the Assignors have agreed to assign all rights, title and interest in and to the Patents to Syntaxin, and Ipsen has agreed to assign all of its rights, title and interest in and to the Licensed Intellectual Property and the Ipsen Assigned Patents to Syntaxin, on the terms and conditions set out in this Assignment.

NOW THIS ASSIGNMENT WITNESSES as follows:

1. Definitions

"HPA Licence Agreement"

means the agreement entered into between the HPA and The Speywood Laboratory Limited dated 10 November 1998;

“Intellectual Property”

means all intellectual property rights including all registered and unregistered trade marks, patents, service marks, trade secrets, design rights (whether registrable or otherwise), applications for any of the foregoing, copyrights and other rights in works of authorship (including rights in computer software), database rights, know-how, all rights to have confidential information kept confidential and all other similar rights or obligations in any country (including the United Kingdom) for the full term of the rights together with any extensions or renewals;

“Licensed Intellectual Property”

means any and all Intellectual Property licensed by Ipsen (the successor to The Speywood Laboratory Limited) to HPA under the HPA License Agreement, including the TSL Background Intellectual Property, the TSL Foreground Intellectual Property, the Joint Intellectual Property and the Joint Materials (the “TSL Background Intellectual Property”, the “TSL Foreground Intellectual Property”, the “Joint Intellectual Property” and the “Joint Materials” being defined in the HPA Licence Agreement), other than the Patents and Ipsen Assigned Patents;

“Subscription Agreement”

means the agreement for the subscription for Ordinary Shares of Syntaxin between the Assignors, Syntaxin, Abingworth Bioventures IV LP, Abingworth Bioventures IV Executives LP, the HPA and others dated 10 November 2005.

1.1 Interpretation

In this Assignment:

- 1.1.1 the headings to the clauses are for convenience only and shall not affect the interpretation or construction of this Assignment;
- 1.1.2 words importing the singular only shall include the plural and vice versa, words importing the masculine shall include the feminine and the neuter and words importing persons shall include bodies incorporated and unincorporated;
- 1.1.3 reference to any statute or statutory provision includes a reference to that statute or statutory provision as from time to time amended, extended or re-enacted; and

1.1.4 reference to the words 'includes' or 'including' shall be construed without limitation to the generality of the preceding words.

2. Assignment of the Licensed Intellectual Property, Patents and Ipsen Assigned Patents

- 2.1 In consideration of payment of £1, receipt of which is acknowledged by Ipsen, Ipsen with full title guarantee (other than with respect to infringement claims of third parties, in respect of which Ipsen shall give no guarantee to Syntaxin) hereby assigns free of all encumbrances to Syntaxin the Licensed Intellectual Property and all of Ipsen's property, right, title and interest in the Ipsen Assigned Patents, including the right to apply for patent or similar protection in relation to any patent applications comprising part of the Licensed Intellectual Property or Ipsen Assigned Patents in any part of the world (including the right to rely on any convention priority period) and all know-how exclusively necessary to practice the Ipsen Assigned Patents, each as was in existence at the date of the Syntaxin Licence Agreement or as developed pursuant to the terms of the Syntaxin Licence Agreement (as applicable), and all property, right, title and interest therein together with the right to sue for and recover damages in respect of all infringements and threatened infringements of the Licensed Intellectual Property and Ipsen Assigned Patents, prior to the date hereof.
- 2.2 HPA and Ipsen each warrant that they are the joint owners of the Patents and Ipsen Assigned Patents, and that no other person has any property, right, title or interest in the Patents or Ipsen Assigned Patents. For the avoidance of doubt, this clause does not affect the meaning of clause 2.4, and HPA shall not be liable for any act or omission of Ipsen which results in breach of this clause and Ipsen shall not be liable for any act or omission of HPA which results in breach of this clause.
- 2.3 HPA shall retain all its property, right, title and interest in the Ipsen Assigned Patents, such that upon completion of the assignment referred to in clause 2.1, HPA and Syntaxin shall be the joint owners of the Ipsen Assigned Patents.
- 2.4 In consideration of payment of £1, receipt of which is acknowledged by HPA and Ipsen, the Assignors each with full title guarantee (other than with respect to infringement claims of third parties, in respect of which the Assignors shall give no guarantee to Syntaxin) hereby assign free of all encumbrances to Syntaxin the Patents, including the right to apply for patent or similar protection in relation to any patent applications comprising part of the Patents in any part of the world (including the right to rely on any convention priority period) and all know-how exclusively necessary to practice the Patents, each as was in existence at the date of the Syntaxin Licence Agreement or as developed pursuant to the terms of the Syntaxin Licence Agreement (as applicable), and all property, right, title and interest therein together with the right to sue for and recover damages in respect of all infringements and threatened infringements of the Patents, prior to the date hereof.
- 2.5 The parties acknowledge that immediately following the assignment of the Licensed Intellectual Property, Patents and Ipsen Assigned Patents to Syntaxin under clause 2 of this Assignment, the HPA Licence Agreement shall automatically terminate in accordance with clause 3.2 of the Variation Agreement.

3. Required Assistance

3.1 Upon request by Syntaxin, each Assignor shall at its own reasonable cost and without unreasonable delay:

3.1.1 in the event that any proceedings are commenced relating to the validity, scope, inventorship and/or ownership of the Licensed Intellectual Property, Patents or Ipsen Assigned Patents pursuant to which the Assignors have or can procure information which may assist in defending such challenge, each Assignor shall supply or procure the supply of such information;

3.1.2 at any time, execute any further documents and carry out any acts reasonably required to give effect to this Assignment.

3.2 Without in any way limiting clause 3.1, upon request by Syntaxin:

3.2.1 Ipsen shall at its own reasonable cost and without unreasonable delay execute all such documents and do all such acts as may be necessary for procuring the grant of patents pursuant to patent applications comprising the Licensed Intellectual Property, Patents and Ipsen Assigned Patents in the name of Syntaxin (or in the case of the Ipsen Assigned Patents, in the joint names of Syntaxin and HPA); and

3.2.2 HPA shall at its own reasonable cost and without unreasonable delay assist with the prosecution of the patent applications comprising the Patents and Ipsen Assigned Patents and execute all such documents and do all such acts as may be necessary for procuring the grant of patents pursuant to such patent applications in the name of Syntaxin (or in the case of the Ipsen Assigned Patents, in the joint names of Syntaxin and HPA).

4. Moral Rights

The Assignors each waive all moral rights in respect of the Licensed Intellectual Property, Patents and Ipsen Assigned Patents that arise under the Copyright, Designs and Patents Act 1988 or any other similar or analogous rights throughout the world, to the fullest extent permissible by applicable law.

5. Further Assurance

The Assignors each covenant with Syntaxin that they shall, at their own reasonable cost and at the direction of Syntaxin, do all such further acts and execute all such documents as may from time to time be necessary to vest in Syntaxin all Licensed Intellectual Property and Patents, and all of Ipsen's property, right, title and interest in the Ipsen Assigned Patents, and the Assignors each hereby irrevocably appoint Syntaxin as its attorney to do all such further acts and execute such documents only as may be strictly necessary for such purpose.

6. Non-Waiver

6.1 Any failure or delay in enforcing an obligation or exercising a right under this Assignment does not amount to a waiver of that obligation or right.

- 6.2 The waiver of a breach of a term of this Assignment does not amount to a waiver of any other term.
- 6.3 A waiver of a breach of any of the terms of this Assignment will not prevent a party from subsequently requiring compliance with the waived obligation.

7. Entire Agreement

This Assignment, the Variation Agreement, the Syntaxin Licence Agreement, the HPA Licence Agreement and the Subscription Agreement constitute the whole agreement and understanding between the parties with respect to the subject matter of this Assignment and supersede all prior agreements, negotiations and discussions between the parties relating to the subject matter of this Assignment.

8. Law of Property (Miscellaneous Provisions) Act 1994

All references to "full title guarantee" in this Assignment shall have the same meaning as set out in the Law of Property (Miscellaneous Provisions) Act 1994.

9. Third Party Rights

No third party shall have the right to enforce any provision of this Assignment by virtue of the Contracts (Rights of Third Parties) Act 1999.

10. Governing Law

This Assignment shall be governed by English law and the parties hereto submit to the exclusive jurisdiction of the English Courts.

12 Counterparts

This Assignment may be entered into in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF the parties hereto have executed this Assignment as a deed on the day and year first above written

EXECUTED AS A DEED
for and on behalf
of the Ipsen Limited
acting by

)
)
)

Alex Stokes

Signature of director

[Signature]

Signature of director / company secretary
(Please delete as applicable)

A. M. STOKES

Name of director (print)

J. C. DAVIS

Name of director/company secretary (print)

EXECUTED AS A DEED
for and on behalf
of the Health Protection Agency
acting by

)
)
)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)

EXECUTED AS A DEED
for and on behalf
of Syntaxin Limited
acting by

)
)
)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)

IN WITNESS WHEREOF the parties hereto have executed this Assignment as a deed on the day and year first above written

EXECUTED AS A DEED

for and on behalf
of the Ipsen Limited
acting by

)
)
)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)


EXECUTED AS A DEED

for and on behalf
of the Health Protection Agency
acting by


)
)
)




Signature of director



Signature of director / company secretary
(Please delete as applicable)



Name of director (print)



Name of director/company secretary (print)

EXECUTED AS A DEED

for and on behalf
of Syntaxin Limited
acting by

)
)
)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)

IN WITNESS WHEREOF the parties hereto have executed this Assignment as a deed on the day and year first above written

EXECUTED AS A DEED

for and on behalf)
of the Ipsen Limited)
acting by)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)

Name of director/company secretary (print)

EXECUTED AS A DEED

for and on behalf)
of the Health Protection Agency)
acting by)

Signature of director

Signature of director / company secretary
(Please delete as applicable)

Name of director (print)


Name of director/company secretary (print)

EXECUTED AS A DEED

for and on behalf)
of Syntaxin Limited)
acting by)



Signature of director



Signature of ~~director~~ / company secretary
(Please delete as applicable)

CHARLES RICHARD POWN
Name of director (print)

MR PHILIP JAMES BOYD
Name of ~~director~~ / company secretary (print)

SCHEDULE 1

PATENTS AND APPLICATIONS

M&S Ref.	Country	Title	Application Date	Application No.	Registration No.	Case Status
P21092AT-EPC-PCT	Austria	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092AU-PCT	Australia	Novel agent for controlling cell activity	18/03/1994	62175/94	671203	Granted
P21092BE-EPC-PCT	Belgium	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092BR-PCT	Brazil	Novel agent for controlling cell activity	18/03/1994	PI1100053-8	PI1100053-8	Granted
P21092CA-PCT	Canada	Novel agent for controlling cell activity	18/03/1994	2158647		Pending
P21092CH-EPC-PCT	Switzerland & Liechtenstein	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092CN-PCT	China	Novel agent for controlling cell activity	18/03/1994	94192125.5	ZL94192125.5	Granted
P21092CZ-PCT	Czech Republic	Novel agent for controlling cell activity	18/03/1994	PV1995-2426		Abandoned
P21092DE-EPC-PCT	Germany	Novel agent for controlling cell activity	18/03/1994	94909262.1	69431832.9	Granted
P21092DK-	Denmark	Novel agent for	18/03/1994	94909262.1	0689459	Granted

Error! Unknown document property name.

EPC-PCT

controlling cell
activity

Error! Unknown document property name.

P21092EP-PCT	European Patent Office	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092ES-EPC-PCT	Spain	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092FI-PCT	Finland	Novel agent for controlling cell activity	18/03/1994	954390		Abandoned
P21092FR-EPC-PCT	France	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092GB-EPC-PCT	United Kingdom	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092GR-EPC-PCT	Greece	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092HK-PCT	Hong Kong	Novel agent for controlling cell activity	18/03/1994	97101926.1		Abandoned
P21092HU-PCT	Hungary	Novel agent for controlling cell activity	18/03/1994	P9502673	217220	Abandoned
P21092IE-EPC-PCT	Ireland	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092IL	Israel	Novel agent for controlling cell activity	20/03/1994	109045		Abandoned

P21092IN	India	Novel agent for controlling cell activity	21/03/1994	200/MAS/94	178499	Abandoned
P21092IT-EPC-PCT	Italy	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092JP-PCT	Japan	Novel agent for controlling cell activity	18/03/1994	520806/1994		Pending
P21092KP-PCT	Democratic People's Republic of Korea	Novel agent for controlling cell activity	18/03/1994	P95-505		Abandoned
P21092KR-PCT	Republic of Korea	Novel agent for controlling cell activity	18/03/1994	95-703985		Abandoned
P21092LU-EPC-PCT	Luxembourg	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092NL-EPC-PCT	Netherlands	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092NO-PCT	Norway	Novel agent for controlling cell activity	18/03/1994	953643		Abandoned
P21092NZ-PCT	New Zealand	Novel agent for controlling cell activity	18/03/1994	262484	262484	Abandoned
P21092PL-PCT	Poland	Novel agent for controlling cell activity	18/03/1994	P310698	178895	Abandoned

P21092PT-EPC-PCT	Portugal	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092RU-PCT	Russian Federation	Novel agent for controlling cell activity	18/03/1994	95117960		Abandoned
P21092SE-EPC-PCT	Sweden	Novel agent for controlling cell activity	18/03/1994	94909262.1	0689459	Granted
P21092SG-PCT	Singapore	Novel agent for controlling cell activity	18/03/1994	9607056-0	73411	Abandoned
P21092SK-PCT	Slovak Republic	Novel agent for controlling cell activity	18/03/1994	PV1155/95		Abandoned
P21092UA-PCT	Ukraine	Novel agent for controlling cell activity	18/03/1994	95094185		Abandoned
P21092US-C1-PCT	United States of America	Novel agent for controlling cell activity	18/03/1994	09/572431		Pending
P21092US-C2-PCT	United States of America	Novel agent for controlling cell activity	18/03/1994			Not yet Filed
P21092US-PCT	United States of America	[Agents per se] Novel agent for controlling cell activity	18/03/1994	08/513878		Abandoned
P21092WO	PCT	Novel agent for controlling cell activity	18/03/1994	PCT/GB94/00558		See National Phase

P21093AT-EPC-PCT	Austria	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093AU-PCT	Australia	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	53398/96	705924	Granted
P21093BE-EPC-PCT	Belgium	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093BG-PCT	Bulgaria	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	101984		Abandoned
P21093BR-PCT	Brazil	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	PI9609870-8		Pending
P21093CA-PCT	Canada	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	2218857		Pending

P21093CH- EPC-PCT	Switzerland & Liechtenstein	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093CN-PCT	China	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	96194505.2	ZL96194505.2	Granted
P21093CZ-PCT	Czech Republic	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	PV1997-3322		Abandoned
P21093DE- EPC-PCT	Germany	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093DK- EPC-PCT	Denmark	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093EP-PCT	European Patent Office	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	96910091.6	0826051	Granted

P21093ES-EPC-PCT	Spain	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093FI-EPC-PCT	Finland	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093FR-EPC-PCT	France	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093GB	United Kingdom	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	21/04/1995	9508204.6		Priority Only
P21093GB-EPC-PCT	United Kingdom	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093GE-PCT	Georgia	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	002909		Abandoned

P21093GR- EPC-PCT	Greece	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093HK	Hong Kong	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	98102094.4		Abandoned
P21093HU-PCT	Hungary	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	P9802392		Abandoned
P21093IE-EPC- PCT	Ireland	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093IN-PCT	India	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	660/MAS/96		Abandoned
P21093IT-EPC- PCT	Italy	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted

P21093JP-PCT	Japan	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	531546/1996	Pending
P21093KP-PCT	Democratic People's Republic of Korea	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97-0779	Abandoned
P21093KR-PCT	Republic of Korea	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97-707466	Abandoned
P21093LT-EPC-PCT	Lithuania	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	Granted
P21093LU-EPC-PCT	Luxembourg	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	Granted
P21093LV-EPC-PCT	Latvia	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	Granted

P21093MX-PCT	Mexico	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	978124		Abandoned
P21093NL-EPC-PCT	Netherlands	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted
P21093NO-PCT	Norway	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	974845		Abandoned
P21093NZ-PCT	New Zealand	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	305411	305411	Abandoned
P21093PL-PCT	Poland	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	P323006		Abandoned
P21093PT-EPC-PCT	Portugal	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	0826051	Granted

P21093RO-PCT	Romania	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97-01963	Abandoned
P21093RU-PCT	Russian Federation	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97119181	Abandoned
P21093SE-EPC-PCT	Sweden	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	Granted
P21093SG-PCT	Singapore	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	18/03/1996	9606595-8	Abandoned
P21093SI-EPC-PCT	Slovenia	Botulinum toxin derivatives able to modify peripheral sensory afferent functions	16/04/1996	0826051	Granted
P21093SK-PCT	Slovak Republic	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	PV1435-97	Abandoned

P21093TR-PCT	Turkey	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97/01215	Abandoned
P21093TW	Taiwan	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	18/04/1996	85104635	Abandoned
P21093UA-PCT	Ukraine	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	97105144	Abandoned
P21093US-C1-PCT	United States of America	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	09/447356	6395513
P21093US-C2-PCT	United States of America	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	10/150262	6962703
P21093US-C3-PCT	United States of America	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	11/234250	Pending

P21093US-C4-PCT	United States of America	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996		Not yet Filed
P21093US-C5-PCT	United States of America	[Hybrid serotypes] Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996		Not yet Filed
P21093US-C6-PCT	United States of America	[EGF] Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996		Not yet Filed
P21093US-PCT	United States of America	[DNA claims] Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	5989545 08/945037	Granted
P21093WO	PCT	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	16/04/1996	PCT/GB96/00916	See National Phase

P21093ZA	South Africa	Clostridial toxin and derivatives able to modify peripheral sensory afferent functions	19/04/1996	96/3129	96/3129	Abandoned
----------	--------------	--	------------	---------	---------	-----------

P21094AT-EPC-PCT	Austria	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094AU-PCT	Australia	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	93574/98	741456	Granted
P21094BE-EPC-PCT	Belgium	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094CA-PCT	Canada	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	2306350		Pending
P21094CH-EPC-PCT	Switzerland & Liechtenstein	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted

P21094DE- EPC-PCT	Germany	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	69814858.4	Granted
P21094DK- EPC-PCT	Denmark	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094EP-PCT	European Patent Office	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094ES-EPC- PCT	Spain	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094FI-EPC- PCT	Finland	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted

P21094FR-EPC-PCT	France	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094GB	United Kingdom	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	08/10/1997	9721189.0		Priority Only
P21094GB-EPC-PCT	United Kingdom	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094GR-EPC-PCT	Greece	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094IE-EPC-PCT	Ireland	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted

P21094IN	India	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	2235/MAS/98	Abandoned
P21094IT-EPC- PCT	Italy	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1 0996468	Granted
P21094JP-PCT	Japan	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	514674/2000	Pending
P21094LU-EPC- PCT	Luxembourg	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1 0996468	Granted
P21094NL- EPC-PCT	Netherlands	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1 0996468	Granted

P21094PT-EPC-PCT	Portugal	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094SE-EPC-PCT	Sweden	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98946571.1	0996468	Granted
P21094TW	Taiwan	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	08/01/1998	87116712		Abandoned
P21094US-C1-PCT	United States of America	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	11/257500		Pending
P21094US-PCT	United States of America	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	09/529130	7052702	Granted

P21094WO	PCT	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	PCT/GB98/03001	See National Phase
P21094ZA	South Africa	Conjugates of galactose-binding lectins and clostridial neurotoxins as analgesics	07/10/1998	98/9138	Abandoned

SCHEDULE 2

IPSEN ASSIGNED PATENTS

M&S Ref.	Country	Title	Application Date	Application No.	Registration No.	Case Status
P19250AT-EPC-PCT	Austria	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250AU-PCT	Australia	Recombinant toxin fragments	22/08/1997	43895/97	723397	Granted
P19250BE-EPC-PCT	Belgium	Recombinant toxin fragments	22/08/1997	97942091.0	0939818	Granted
P19250CA-PCT	Canada	Recombinant toxin fragments	22/08/1997	2264191		Pending
P19250CH-EPC-PCT	Switzerland & Liechtenstein	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250DE-EPC-PCT	Germany	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250DK-EPC-PCT	Denmark	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250EP-PCT	European Patent Office	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250FR-EPC-PCT	France	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted
P19250GB	United Kingdom	Recombinant toxin fragments	23/08/1996	9617671.4		Priority Only
P19442GB	United Kingdom	Recombinant toxin fragments	13/12/1996	9625996.5		Priority Only
P19442US	United States of America	Recombinant toxin fragments	27/12/1996	08/782893		Abandoned
P19442TW	Taiwan	Recombinant toxin fragments	28/1/1997	86100912		Abandoned
P19250GB-EPC-	United Kingdom	Recombinant toxin fragments	22/08/1997	97942094.0	0939818	Granted

